SCNI

Scinai Immunotherapeutics Ltd.

The mega-cap semiconductors are breaking out on real earnings and AI demand, which is dominating the session, while liquidity is flowing into infrastructure and growth plays. $KBLB, $GOOG, $NVND, $INTC, $AMD, $POET, $CTNT, $SCNI

Biotech investors spent much of the past year pulling back from speculative microcap names as higher rates, tighter capital markets, and regulatory uncertainty pressured valuations across the sector. That trend has started to shift as targeted institutional money moves back into select names, particularly in immunology, inflammation therapeutics, and the contract development and manufacturing organization (CDMO) space, where pharmaceutical companies continue diversifying manufacturing capacity and supply chain exposure.Shares of Scinai Immunotherapeutics (NASDAQ: SCNI) are surging Friday ...

Biotech investors spent much of the past year pulling back from speculative microcap names as higher rates, tighter capital markets, and regulatory uncertainty pressured valuations across the sector. That trend has started to shift as targeted institutional money moves back into select names, particularly in immunology, inflammation therapeutics, and the contract development and manufacturing organization (CDMO) space, where pharmaceutical companies continue diversifying manufacturing capacity and supply chain exposure.Shares of Scinai Immunotherapeutics (NASDAQ: SCNI) are surging Friday ...

Scinai Immunotherapeutics shares are surging Friday after it announced fresh financing tied to a private placement and warrant exercise.read more...

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing PR Newswire JERUSALEM, April 24, 2026...

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities Scinai Completes Strategic Reorganization to Establish Dedicated CDMO...

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and...

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at...

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price PR Newswire JERUSALEM, March 16...